BioNTech SE (BNTX) Receivables (2018 - 2026)

BioNTech SE has reported Receivables for 8 years, with the latest figure at $11.8 million in Q4 2025.

• Quarterly Receivables fell 44.43% year-over-year to $11.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.8 million (down 44.43% YoY) and the FY2025 annual result came in at $1.0 billion, down 33.25% from the prior year.
• Receivables fell to $11.8 million in Q4 2025 per BNTX's latest filing, from $807.6 million in the prior quarter.
• Over five years, Receivables peaked at $14.2 billion in Q1 2022 and troughed at $5.3 million in Q4 2023.
• A 5-year average of $4.0 billion and a median of $1.8 billion in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2021 and 2024: Receivables surged 7078.2% in 2021, then slumped 97.18% in 2024.
• Over 5 years, Receivables stood at $14.2 billion in 2021, then sank by 47.97% to $7.4 billion in 2022, then sank by 99.93% to $5.3 million in 2023, then jumped by 301.32% to $21.2 million in 2024, then slumped by 44.43% to $11.8 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $11.8 million, $807.6 million, and $1.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.